Equities

AstraZeneca PLC

AZN:LSE

AstraZeneca PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)14,104.00
  • Today's Change124.00 / 0.89%
  • Shares traded3.06m
  • 1 Year change19.67%
  • Beta0.8573
Data delayed at least 20 minutes, as of Feb 06 2026 16:33 GMT.
More ▼

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year AstraZeneca PLC grew revenues 18.03% from 45.81bn to 54.07bn while net income improved 18.14% from 5.96bn to 7.04bn.
Gross margin81.90%
Net profit margin16.18%
Operating margin22.02%
Return on assets8.57%
Return on equity21.70%
Return on investment11.81%
More ▼

Cash flow in USDView more

In 2024, AstraZeneca PLC did not generate a significant amount of cash. However, the company earned 11.86bn from its operations for a Cash Flow Margin of 21.94%. In addition the company used 7.98bn on investing activities and also paid 4.00bn in financing cash flows.
Cash flow per share6.99
Price/Cash flow per share19.90
Book value per share21.74
Tangible book value per share-6.41
More ▼

Balance sheet in USDView more

AstraZeneca PLC has a Debt to Total Capital ratio of 41.52%, a lower figure than the previous year's 73.66%.
Current ratio0.8792
Quick ratio0.6856
Total debt/total equity0.7111
Total debt/total capital0.4152
More ▼

Growth rates in USD

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 5.97% and 18.06%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is in-line with the industry average relative to its peers, while earnings per share growth is the highest in its industry.
Div yield(5 year avg)2.35%
Div growth rate (5 year)1.20%
Payout ratio (TTM)52.05%
EPS growth(5 years)34.41
EPS (TTM) vs
TTM 1 year ago		44.74
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.